Reviva Pharmaceuticals Q4 EPS $(0.35) Misses $(0.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals (NASDAQ:RVPH) reported Q4 losses of $(0.35) per share, missing the consensus estimate of $(0.32) by 9.37%. This represents a 7.89% improvement over the $(0.38) per share loss from the same period last year.
April 15, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Reviva Pharmaceuticals reported a Q4 loss per share of $(0.35), missing estimates by 9.37% but improving from last year's $(0.38) loss.
Missing the earnings estimate typically results in negative investor sentiment in the short term, leading to potential stock price decline. However, the improvement over last year's loss may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100